Deutsche Bank analyst Barbara Ryan initiates coverage on the Pharmaceutical Distribution Sector
Ryan discusses the impact the new fee-for-service compensation model has had on the sector, while acknowledging it is almost complete and that it brings certain advantages to investors. "Distributors have suffered margin compression in the conversion to a new fee-for-service compensation model with pharmaceutical manufacturers," she said. "Despite providing fewer opportunities for increased profits due to speculative buying, the new methodology increases earnings visibility and cash flow."
Deutsche Bank was recently ranked the top bulge-bracket firm for equities research by an Investars survey of asset managers, research directors, analysts, individual investors and financial institutions. The rankings measured one-year performance of Deutsche Bank's stock picks vs. the S&P 500.
For further information, please call:
Renee Calabro 212-250-5525
About Deutsche Bank
With Euro 901 billion in assets and 64,500 employees, Deutsche Bank offers unparalleled financial services in 74 countries throughout the world. Deutsche Bank competes to be the leading global provider of financial solutions for demanding clients creating exceptional value for its shareholders and people.
Deutsche Bank ranks among the global leaders in corporate banking and securities, transaction banking, asset management, and private wealth management, and has a significant private and business banking franchise in Germany and other selected countries in Continental Europe.
Deutsche Bank Securities Inc. is the investment banking and securities arm of Deutsche Bank AG in the United States.